Bulgaria – Construction, foundation and surface works for highways, roads – „Извършване на строителство, основен ремонт, реконструкция, рехабилитация на пътна и улична мрежа, пътни съоръжения и елементи на техническата инфраструктура за нуждите на Община Ловеч“

Bulgaria – Road construction works – “ИЗБОР НА ИЗПЪЛНИТЕЛ ЗА ПРОЕКТИРАНЕ, УПРАЖНЯВАНЕ НА АВТОРСКИ НАДЗОР И СТРОИТЕЛСТВО (ИНЖЕНЕРИНГ) ЗА ИЗГРАЖДАНЕ НА НОВ ПЪТ, ПРОДЪЛЖЕНИЕ НА ПЪТ PDV- 2340 „СЪЕДИНЕНИЕ - ГОЛЯМ ЧАРДАК – ЦАРИМИР – КАЛОЯНОВО“ ОТ КМ 8+000 ДО КМ 11+700 В ОТСЕЧКА С. ГОЛЯМ ЧАРДАК – С. ЦАРИМИР“

Bulgaria – Footpath construction work – ПРОЕКТИРАНЕ, СТРОИТЕЛСТВО И АВТОРСКИ НАДЗОР ЗА ОБЕКТ: РЕХАБИЛИТАЦИЯ НА ТРОТОАРИ В ГР. ЛОМ И В СЕЛАТА ДОБРИ ДОЛ, ОРСОЯ, СЛИВАТА ПО ПРОТЕЖЕНИЕТО НА ПЪТ II-11 (С. ДОБРИ ДОЛ, С. ОРСОЯ, С. СЛИВАТА) В РАМКИТЕ НА ПРОЕКТ BG16FFPR003-2.006-0109-C01 КИТИ НА ТЕРИТОРИЯТА НА ОБЩИНИТЕ ЛОМ, ДИМОВО И ОРЯХОВО ПО ПРОЦЕДУРА BG16FFPR003-2.002 ПОДКРЕПА ЗА ИГР В 40 ГРАДСКИ ОБЩИНИ НА ПРР 2021-2027 Г.

Bulgaria – Road-repair works – „Определяне на изпълнител за извършване на дейности по ремонт и поддържане на общински пътища и части от републикански пътища извън урбанизираните територии на населените места на територията на Община Поморие“

Bulgaria – Roof works and other special trade construction works – „Текущ ремонт на покрив на 94 СУ „Димитър Страшимиров“, УПИ I, кв. 46, гр. София, ул. „511“ № 22, СО - район „Слатина“

Ireland – Houses construction work – TEN2600141 - CfT for Construction of 44 Units at Lios na Ri, Cootehill, Co. Cavan for Cavan County Council

Italy – Construction work for buildings relating to leisure, sports, culture, lodging and restaurants – Procedura aperta, sopra soglia comunitaria, per l'esecuzione dei lavori relativi all'intervento B10.3 "Riqualificazione della piazza ex-Mercato nel comune di Cortina d'Ampezzo (BL)" di cui all'Allegato 1 al d.P.C.M. dell'08.09.2023

Expected Outcome: This action will establish a strategic European initiative to develop scalable, modular, and interoperable photonic quantum computing platforms. Proposals for this topic are expected to address and provide credible solutions to at least two major technical roadblocks currently limiting the advancement of photonic quantum computing such as: The lack of deterministic, high-efficiency photonic entanglement and loss-tolerant architectures suitable for fault-tolerant scaling The absence of a standardised, integrated control stack combining photonic hardware, firmware, and system software with reliable benchmarking across platforms Project results are expected to contribute to the following expected outcomes: By 2028, demonstration of a photonic NISQ processor with ≥100 photonic qubits, integrating deterministic single-photon sources, low-loss waveguides, on-chip detectors, and a firmware stack (scheduler, controller, compiler), validated via hardware-agnostic benchmarks and hybrid photonic-HPC applications demonstrating classical-quantum crossover By 2030, delivery of a full-stack, high-connectivity photonic quantum computer, with modular scalability, integrated…

Expected Impact: The action under this topic is expected to achieve the following impacts and contribute to the following EU policies/initiatives: deliver innovative, early technology solutions that contribute to addressing strategic unmet public health needs across multiple therapy areas to improve prevention, early diagnosis, and treatment; leverage the unique network and scale of IHI JU members to create a pipeline to support innovative startups in the health industry, fully integrated into European initiatives in support of start-ups and entrepreneurship; drive early cross-sector health R&D and innovation to strengthen the European healthcare industry’s global competitiveness, contributing to the EU Industrial Strategy and Pharmaceutical Strategy objectives; create a sustainable network of European healthcare incubators to guide and support highly talented and innovative early-stage companies; harness digital health and data-sharing technologies (e.g., AI and big data) to enable interoperable health solutions, contributing to the European Health Data Space (EHDS) and improved evidence based care;- the action should generate a portfolio of early‑stage companies that have…

Expected Impact: The action under this topic is expected to achieve the following impacts: Accelerate EU access to more cost-effective interventions in an increasingly ageing population by identifying personalised treatment approaches for elderly-onset immune diseases. Decrease disease risk later in life by defining specific prevention strategies based on ageing biomarkers and risk factors. Halt age-associated disease exacerbation by the identification of predictive and digital biomarkers that can stratify patients for early intervention. Improve quality of life for healthy individuals and patients by preventing further health decline, avoiding escalating care costs, and properly stratifying individuals earlier in the diagnostic pathway. Accelerate adoption of innovative diagnostic, preventative, and therapeutic strategies, strengthening the EU’s position as a healthcare innovator. Evaluate digital biomarker as potential regulatory endpoints in the ultimate goal to develop medicines for ‘healthy ageing’. Integrate fragmented research efforts by bringing together health industry sectors and stakeholders to develop clinical and multi-omics data integration capabilities. Enable new…

Expected Impact: The action under this topic is expected to achieve the following impacts: Faster and more informed decision-making through the use of an AI-driven NAM (AI Foundation Toxicology Model) and increased efficiency through rapid processing of vast amounts of data [1] . Increased consistency and standardisation in a NAM-based approach, specifically an AI model, used by industry in the efficient development, testing and production of safe and effective innovative health technologies, improving industrial competitiveness. Regulatory adoption of a NAM-enabled second species waiver model (AI Foundation Toxicology Model) and weight-of-evidence framework, in line with recommendations and more consistent global decision-making on waiving second species testing. Reduction in animal use, accelerated timelines and lower costs, enhancing the competitiveness of the European health industry through economical and ethical benefits. Improved public health as patients will benefit from safe and effective medicines developed faster using validated NAMs. The action is expected to contribute to the EU Directive (2010/63/EU) [2] on the protection of animals used for scientific purposes and…